This fact reviews how hormone therapy may be used to treat prostate cancer, treatment options for castration-resistant prostate cancer, and side effects of hormone therapy.
Nonadherence to Noncancer Medication Schedules Predicts Adherence to Adjuvant Hormone Therapy for Breast CancerJune 28, 2016
Patients who do not adhere to their medication schedules for chronic conditions prior to a breast cancer diagnosis were twice as likely to skip oral adjuvant hormonal therapy.
Radiotherapy in combination with anti-androgen hormone therapy halves the risk of death from prostate cancer 15 years after diagnosis compared with hormone therapy alone.
Researchers identified a cancer-causing gene triggered by alcohol use, providing a link between alcohol and breast cancer in cell-based research.
Risks of Adverse Effects Lower With Surgical Castration Vs. Chemical Castration for Metastatic Prostate CancerJanuary 07, 2016
Surgical castration via orchiectomy for metastatic prostate cancer is associated with lower risks for adverse effects compared with medical castration via GnRHa therapy.
Data collected from Japanese and Korean participants in the global PALOMA3 trial provide evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with advanced HR+/HER2- breast cancer.
Docetaxel should be added at initiation of standard of care treatment in men with prostate cancer; however, no evidence of survival improvement was seen with zoledronic acid therefore it is not recommended as part of standard of care for this patient population.
Adding continuous progestin to estrogen lowers the risk of endometrial cancer in postmenopausal women, according to a new study.
In a study that demonstrates the emerging technique of extracting biomedical data from ordinary patient medical records, a nearly 2-fold increase was seen in the rate of Alzheimer disease diagnoses among men with prostate cancer who received ADT.
Gene Expression Test Can Lead to More Effective Treatment Decisions In Patients With Invasive Lobular Carcinoma (ILC) Breast CancerNovember 06, 2015
Most patients with invasive lobular carcinoma (ILC) breast cancer could be treated with hormones alone and not with chemotherapy.
Overall survival in men with rising PSA levels after prostatectomy for prostate cancer was statistically improved by adding a 24-month course of AAT during and after salvage radiotherapy, compared with salvage radiotherapy alone.
Researchers discovered a new explanation for why women with ER+ breast cancer develop resistance to hormone treatment, and a potential new approach that may overcome the problem.
In a small clinical trial, scientists found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.
Women with luminal A subtype breast cancer, especially those older than 60 years, may not need radiation treatment if they are already taking hormone therapy.
Researchers are examining what factors might make patients with prostate cancer more likely to experience hot flashes during and after therapy.
Men with prostate cancer that has spread to nearby lymph nodes may find the addition of radiation therapy to treatments that block the effects of testosterone beneficial.
Breast cancer patients given the hormone-blocking drug goserelin during chemotherapy experience less ovarian failure and are more likely to have successful pregnancies, according to study results.
The addition of radiation treatment to hormone therapy reduced more cancer deaths among older men locally advanced prostate cancer, compared to hormone therapy alone.
Current evidence seems to indicated that withholding T therapy in hypogonadal men cannot be justified.
Some prostate cancer medications are linked to an increased risk of dying from heart-related causes in men with congestive heart failure or with a history of prior heart attacks.
A new study suggests a safe and effective role for natural steroid hormones in treating postmenopausal breast cancer, with fewer detrimental side effects and improved health profile than with standard antihormone therapies.
Up to a third of triple-negative breast cancer tumors express the androgen receptor. Trails are underway with drugs to inhibit the androgen receptor in much the same way that tamoxifen inhibits the estrogen receptor in ER-positive breast cancers.
Many patients older than 65 years with localized breast cancer are eligible for adjuvant hormonal therapy, but little is known about why patients start and stop treatment.
A new study is suggesting a different approach to treating prostate cancer. Researchers at Comprehensive Cancer Centers of Nevada conducted a study in which 790 men with advanced stages of prostate cancer received early chemotherapy.
In an international randomized phase III clinical trial, the hormone therapy enzalutamide extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy.
The hormone progesterone could become part of therapy against the most aggressive form of brain cancer.
Except for frail patients, most participants in a large study complied with their oncologists' recommendations to treat their estrogen-positive breast cancer with hormone therapy.
Gonadotropin-releasing hormone-I (GnRH-I) has attracted strong attention as a hormonal therapeutic tool, particularly for androgen-dependent prostate cancer patients. Here, we investigated the effect of SN09-2 on the growth of PC3 prostate cancer cells.
A protein called BET bromodomain protein 4 binds to the androgen receptor downstream of where current therapies work, where it targets androgen receptor signaling. This new study suggests a way to block hormones, since prostate cancer that becomes resistant to current treatments might remain sensitive to a drug that targets BET bromodomain proteins.
Men with prostate cancer that is small and confined to the prostate gland but at risk of growing, do better if they are treated with radiotherapy combined with androgen deprivation therapy.
- Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma
- Comprehensive Report Looks at Benefits and Harms of Medical Cannabis
- Role of Oncology Nurse Navigators Has Evolved and Expanded in 5 Years
- Lutetium-177 Dotatate Improves PFS in Advanced Midgut Carcinoid Tumors
- MABp1 Improves Symptoms vs Placebo in Colorectal Cancer
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Comprehensive Report Looks at Benefits and Harms of Medical Cannabis
- Racial Disparities Persist in Myeloma Treatment Use
- The Affordable Care Act Has Increased the Use of Mammography But Not Colonoscopy
- Screening for Breast Cancer Correlates with Significant Overdiagnosis
- Customers Find Useful Information in Results from Direct-to-Consumer Genetic Testing
- Nilotinib for CML Associated With Improved Quality of Life
- Adding Pioglitazone to Imatinib May Improve Response in CML
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|